Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B

Journal of Viral Hepatitis

Volumn 6, Issue 3, 1999, Pages 183-194

  Hussain, M ^a   Lok, A S F ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Adefovir; Chronic hepatitis B; Famciclovir; Hepatitis B virus DNA; Lamivudine

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; FAMCICLOVIR; LAMIVUDINE; LOBUCAVIR;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENE MUTATION; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; STRUCTURAL GENE; VIRUS INHIBITION; VIRUS LOAD;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, MICROBIAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; RIBONUCLEASE H, CALF THYMUS; RNA-DIRECTED DNA POLYMERASE;

EID: 0033011646     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1999.00160.x     Document Type: Review

References (62)

1. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta analysis. Ann Intern Med 1993; 119: 312-323.
2. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114: 629-634.
3. Lok AS, Chung HT, Liu VW, Ma OC. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993; 105: 1833-1838.
4. Brook MG, Karayannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 761-766.
5. Zoulim F, Trepo C. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J Hepatol 1998; 29: 151-168.
6. Ganem D. Hepadnaviridae and their replication. In: Feilds Virology, 3rd edn. 1996: 2703-2737.
7. Lenhoff RJ, Summers J. Coordinate regulation of replication and virus assembly by the large envelope protein of an avian hepadnavirus. J Virol 1994; 68: 4565-4571.
8. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WM. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997; 71: 9392-9399.
9. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996; 93: 4398-4402.
10. Zeuzem S, de Man RA, Honkoop P, Roth WK, Schalm SW, Schmidt JM. Dynamics of hepatitis B virus infection in vivo. J Hepatol 1997; 27: 431-436.
11. Poch O, Sauvaget I, Delarue M, Tordo N. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J 1989; 8: 3867-3874.
12. Li MD, Bronson DL, Lemke TD, Faras AJ. Phylogenetic analyses of 55 retroelements on the basis of the nucleotide and product amino acid sequences of the pol gene. Mol Biol Evol 1995; 12: 657-670.
13. Johnson MS, McClure MA, Feng DF, Gray J, Doolittle RF. Computer analysis of retroviral pol genes: assignment of enzymatic functions to specific sequences and homologies with nonviral enzymes. Proc Natl Acad Sci USA 1986; 83: 7648-7652.
14. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256: 1783-1790.
15. Kuritzkes DR. Clinical significance of drug resistance in HIV-1 infection. AIDS 1996; 10: S27-S31.
16. Boucher CA, Cammack N, Schipper P et al. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993; 37: 2231-2234.
17. Keulen W, Back NK, van Wijk A, Boucher CA, Berkhout B. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J Virol 1997; 71: 3346-3350.
18. Back NK, Nijhuis M, Keulen W et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996; 15: 4040-4049.
19. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989; 246: 1155-1158.
20. Gao Q, Gu Z, Parniak MA et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′, 3′- dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993; 37: 1390-1392.
21. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269: 696-699.
22. Mulato AS, Lamy PD, Miller MD et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy. Antimicrob Agents Chemother 1998; 42: 1620-1628.
23. Severini A, Liu XY, Wilson JS, Tyrrell DLJ. Mechanism of inhibition of duck hepatitis B virus polymerase by (-) -B-L-2,3-dideoxy-3-thiacytidine. Antimicrob Agents Chemother 1995; 39: 1430-1435.
24. Lai CL, Ching CK, Tung AKM et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo controlled trial. Hepatology 1997; 25: 241-244.
25. Dienstag JL, Perrillo R, Schiff E, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-1661.
26. Nevens F, Main J, Honkoop P et al. Lamivudine therapy for chronic hepatitis B. A six-month randomized dose ranging study. Gastroenterology 1997; 113: 1258-1263.
27. Lai CL, Chien RN, Leung NWY et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-68.
28. Perrillo R, Rakela J, Martin P et al. Lamivudine for suppression and/or prevention of hepatitis B when given pre-/post-liver transplantation (OLT). Hepatology 1997; 26: A526.
29. Grellier L, Mutimer D, Ahmed M et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212-1215.
30. Perrillo R, Rakela J, Martin P et al. Long term lamivudine therapy of patients with recurrent hepatitis B post-liver transplantation. Hepatology 1997; 26: A196.
31. Dienstag JL, Schiff ER, Mitchell M et al. Extended lamivudine retreatment for chronic hepatitis B. Hepatology 1996; 24: A188.
32. Honkoop P, Niesters HGM, deMan RAM, Osterhaus ADME, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997; 26: 1393-1395.
33. Chayama K, Suzuki Y, Kobayashi M et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 1711-1716.
34. Liaw YF, Lai CL, Leung NWY et al. Two-year lamivudine therapy in chronic hepatitis B infection: results of a placebo controlled multicentre study in Asia. Gastroenterology 1998; 114: A1289.
35. Allen MI, Deslauriers M, Andrews CW et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27: 1670-1677.
36. Ling R, Mutimer D, Ahmed M et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711-713.
37. Tillmann HL, Trautwein C, Bock T et al. Response and mutations in patients sequentially treated with lamivudine and famciclovir for recurrent hepatitis B after liver transplantation. Hepatology 1997; 26: A1202.
38. Bartholomew MM, Jansen RW, Jeffers LJ et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20-22.
39. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependant DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714-717.
40. Naoumov NV, Chokshi S, Smith H, Williams R. Emergence and characterisation of lamivudine resistant hepatitis B virus variant. Hepatology 1996; 24: A282.
41. Petit MA, Buffello D, Roche B et al. Residual hepatitis B virus (HBV) infection in liver transplant patients under treatment with lamivudine (3TC): assessment by quantitation of HBV DNA by PCR and assay of preS antigens. Hepatology 1997; 26: A746.
42. Shields PL, Ling R, Harrison T, Boxall E, Elias E, Mutimer DJ. Management and outcome of lamivudine (LAM)-resistant hepatitis B virus (HBV) infection after liver transplantation (LT). Hepatology 1997; 26: A527.
43. Garrett L, Dienstag JL, Gauthier J et al. Hepatitis B e antigen (HBeAg) seroconversion in two patients with evidence of genotypic resistance following extended lamivudine treatment. Hepatology 1997; 26: A1209.
44. Buti M, Jardi R, Cotrina M, Rodriguez-Frias F, Esteban R, Guardia J. Hepatitis flare in a patient with chronic hepatitis B non-responder to lamivudine: emergence of hepatitis B variants. Hepatology 1997; 26: A1436.
45. Rodriguez MJ, Martinez EJ, Magill A et al. Clinical management of hepatitis B recurrence after liver transplantation with lamivudine resistant strains. Hepatology 1997; 26: A1847.
46. Fischer KP, Tyrrell DLJ. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-B-L-2,3-Dideoxy-3-Thiacytidine] in vitro. Antimicrob Agents Chemother 1996; 40: 1957-1960.
47. Jacobo-Molina A, Ding J, Nanni RG et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci USA 1993; 90: 6320-6324.
48. Honkoop P, De Man RA, Heijtink RA, Schalm SW. Hepatitis B reactivation after lamivudine. Lancet 1995; 346: 1156-1157.
49. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27: 628-633.
50. Shaw T, Mok SS, Locarnini SS. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology 1996; 24: 996-1002.
51. Zoulim F, Dannaoui E, Trepo C. Inhibitory effect of penciclovir on the priming of hepadnavirus reverse transcription. Abstract from the 35th International Conference on Antimicrobial Agents and Chemotherapy 1995; A182.
52. Main J, Brown JL, Howells C et al. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hep 1996; 3: 211-215.
53. Trepo C, Jezek P, Atkinson G, Boon R. Efficacy of famciclovir in chronic hepatitis B: results of a dose finding study. Hepatology 1996; 24: A188.
54. Neuhaus P, Manns M, Atkinson G. Safety and efficacy of famciclovir for the treatment of recurrent hepatitis B in liver transplant recipients. Hepatology 1997; 26: A528.
55. Kruger M, Tillmann HL, Trautwein C et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. Liver Transpl Surg 1996; 2: 253-262.
56. Aye TT, Bartholomeusz AI, Shaw T et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997; 26: 1148-1153.
57. Zoulim F, Pichoud C, Wang Z, Aguesse-Germonb S, Trepo C. Hepatitis B virus genome variability during famciclovir therapy. Hepatology 1997; 26: A1200.
58. Heathcote EJ, Jeffers L, Wright T et al. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled phase II studies. Hepatology 1998; 28: A620.
59. Heathcote J, Chan R, McHutchison J et al. A phase II multicenter study of oral lobucavir for treatment of chronic hepatitis B. Hepatology 1998; 28: A621.
60. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997; 26: 216-225.
61. Locarnini SA, Aye TT, Shaw T et al. The emergence of famciclovir resistant mutations in the hepatitis B virus polymerase during therapy in patients following liver transplantation. Hepatology 1997; 26: A958.
62. De Man RA, Bartholomeusz A, Locarnini S, Niesters HGM, Zondervan PE. The occurrence of sequential viral mutations in a liver transplant recipient re-infected with hepatitis B: primary famciclovir resistance followed by a lethal hepatitis during acquired lamivudine resistance. J Hepatol 1997; 26: 77.